Citations

Clear

2391 citation(s) found for "Ma, Lin".

Idecabtagene vicleucel and endogenous T‐cell phenotypes linked to progression‐free survival in relapsed multiple myeloma
Paiva, Bruno , Manrique, Irene , Thompson, Ethan, CAMPBELL, TIMOTHY B., Guerrero, Camila, Martin, Nathan, Anderson, Larry D. , Lonial, Sagar, Raje, Noopur S., Lin, Yi, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., Kaiser, Shari, Paiva, Bruno , Anderson, Larry D , Thompson, Ethan G., Berdeja, Jesús G. , Lonial, Sagar , Moreau, Philippe , San-Miguel, Jesus , Munshi, Nikhil C.

Mayo Clinic

HemaSphere | July 2, 2026 | Volume: 10 | Issue: 7 | Pages: No page available

10.1002/hem3.70423 | PMID 42396130 Get It

Abstract Improved understanding of how chimeric antigen receptor (CAR) and endogenous T‐cell phenotypes associate with progression‐free survival (PFS) is needed to individualize and improve immunotherapy outcomes in multiple myeloma (MM). We characterized and investigated the prognostic value of immune dynamics defined with multidimensional and computational flow cytometry in 258 bone marrow aspirates from 107 MM patients treated with idecabtagene vicleucel in the KarMMa trial. At screening, there was an association between longer PFS and increased percentages of PD1 + cytotoxic T cells and ICOS − TIGIT + Tregs. At Month 1 after infusion, the presence of >1% CAR‐T cells, a CD4/CD8 CAR‐T‐cell ratio >0.09, and greater abundance of non‐activated non‐cytolytic CAR‐T cells identified patients with longer PFS. Notably, 47 of the 115 endogenous T‐cell clusters were prognostic at the latest assessment performed after CAR‐T infusion. Lower percentages of ICOS + TIGIT − Tregs showed the strongest association with longer PFS. Altogether, this large dataset of dynamic immune profiling throughout treatment with anti‐B‐cell maturation antigen (anti‐BCMA) CAR‐T cells uncovered that the T‐cell composition prior to apheresis as well as CAR‐T and endogenous T‐cell phenotypes after infusion associates with PFS. These findings have potential for translation into routine laboratory practice for improved understanding of response and resistance to CAR‐T cells in relapsed/refractory MM.
Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma
Lim, Kenneth J C , Kumar, Shaji, Chhabra, Saurabh , Tan, Melinda Si Yun , Dooley, Katharine, Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Yi L. , Stephens, Haily, Kapoor, Prashant , Kourelis, Taxiarchis, Warsame, Rahma, Abdallah, Nadine , Bergsagel, P. Leif, Yadav, Udit, Geyer, Susan M. , Ailawadhi, Sikander, Lin, Yi, Zanwar, Saurabh , Chhabra, Saurabh , Tan, Melinda , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Wiedmeier-Nutor, Julia E , Geyer, Susan , Rajkumar, S Vincent , Fonseca, Rafael , Zanwar, Saurabh S , Lim, Kenneth J C , Kumar, Shaji , Parrondo, Ricardo D , Dooley, Katharine , Stephens, H. J. B., Kourelis, Taxiarchis , Warsame, Rahma , Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier, Julia E. , Rajkumar, S. Vincent , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

American Journal of Hematology | June 26, 2026 | Volume: 101 | Issue: 9 | Pages: 2269-2279

10.1002/ajh.70425 | PMID 42351384 Get It

ABSTRACT Ciltacabtagene autoleucel (cilta‐cel) has demonstrated excellent efficacy and long‐term disease control in patients with relapsed/refractory multiple myeloma (RRMM). However, a proportion of patients experience early treatment failures. We investigated clinical factors associated with early progression or death (within 12 months) in patients with RRMM receiving standard‐of‐care cilta‐cel across the three Mayo clinic centers. Patients with a follow‐up of at least 12 months or progression or death within 12 months from infusion were included. Of the patients with early treatment failure ( n = 52), 69% had progressive disease and 31% had a non‐relapse mortality (NRM) event. In patients without early treatment failure ( n = 164), 13% of events were NRM. Among pretreatment factors, prior BCMA‐directed therapy, presence of extramedullary disease and a CAR‐HEMATOTOX score of ≥ 2 were independent predictors of early progression or death. The utilization of cilta‐cel in earlier lines of treatment (1–3 vs. 4 or more) demonstrated comparable PFS (12‐month PFS 73% vs. 77%, p = 0.94). Measurable residual disease positivity in the bone marrow at 3 months (11/197 patients) identified a small but high‐risk group with an increased risk of early treatment failure (OR 5.68; p = 0.012). Patients with less than a complete response on a FDG PET/CT at 3 months also had an increased risk of early treatment failure (OR 11.8; p < 0.0001). Our findings may help identify patients at high‐risk for early adverse outcomes despite receiving highly effective therapy, and support consideration of novel therapeutic strategies within a clinical trial setting.
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Othman, Tamer , Roloff, Gregory W. , Miller, Katharine, Zhang, Amy , Sutherland, Katherine C. , Faramand, Rawan , Hill, LaQuisa C. , Jeyakumar, Nikeshan , Ladha, Abdullah , Kopmar, Noam E., Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Solh, Melhem , Guzowski, Caitlin, Tan, Virginia, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul , Mountjoy, Luke, Schwartz, Marc S., Connor, Matthew P. , Vasu, Sumithira, Kumaran, Muthu, Hoeg, Rasmus T., Tracy, Sean , Yaghmour, George , Pullarkat, Vinod , Muffly, Lori , Aldoss, Ibrahim, Jeyakumar, Nikeshan , Ladha, Abdullah , Sasine, Joshua , Lin, Chenyu , Hilal, Talal , Majhail, Navneet S , Dykes, Kaitlyn C , Logan, Aaron C , Connor, Matthew , Cassaday, Ryan D , Leonard, Jessica T , Shah, Bijal , Frey, Noelle V , Muffly, Lori , Hill, LaQuisa C , Faramand, Rawan , Sutherland, Katherine , Roloff, Gregory W , Othman, Tamer , Zhang, Amy , Muhsen, Ibrahim N. , Sasine, Joshua , Lin, Chenyu , Kopmar, Noam E. , Tsai, Stephanie, Hilal, Talal , Majhail, Navneet S. , Battiwalla, Minoo , Malik, Shahbaz A. , Mountjoy, Luke , Dykes, Kaitlyn C. , Wang, Jiasheng , Vasu, Sumithira , Hoeg, Rasmus T. , Yalniz, Fevzi , Cassaday, Ryan D. , Shah, Bijal , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020707 | PMID 42349018 Get It

Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.
Clinical course, risk factors, and therapeutic response in multiple myeloma with central nervous system involvement
Xiao, Alexander , Zanwar, Saurabh , Lin, Yi, Kapoor, Prashant , Abdallah, Nadine , Baudi, Francis, Dingli, David, Gertz, Morie A. , Gonsalves, Wilson I, Hayman, Suzanne R. , Kourelis, Taxiarchis , Tan, Melinda SY, Warsame, Rahma , Rajkumar, S Vincent, Kumar, Shaji , Dingli, David , Buadi, Francis K. , Lin, Yi , Lin, Yi , Buadi, Francis K , Binder, Moritz , Dispenzieri, Angela , Dingli, David , Gertz, Morie A , Gonsalves, Wilson , Kourelis, Taxiarchis , Leung, Nelson , Muchtar, E , Siddiqui, Mustaqeem A , Tan, Melinda , Warsame, Rahma , Rajkumar, S Vincent , Kumar, Shaji K , Xiao, Alexander H , Binder, Moritz , Dispenzieri, Angela , Gonsalves, Wilson I. , Leung, Nelson , Muchtar, Eli , Siddiqui, Mustaqeem , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: 10 | Issue: 17 | Pages: 5828-5833

10.1182/bloodadvances.2026020668 | PMID 42348786 Get It

Abstract Extramedullary disease (EMD) is increasingly recognized in relapsed/refractory multiple myeloma (MM), with central nervous system involvement (CNS-MM) representing a rare but highly aggressive manifestation associated with dismal outcomes. Data on its incidence and optimal management, particularly in the era of cellular and bispecific therapies, remain limited. We conducted a retrospective analysis of patients with MM with pathology-confirmed EMD treated at our institution between January 2000 and December 2023. CNS-MM was defined by parenchymal or leptomeningeal involvement. Clinical features, cytogenetics, treatments, and outcomes were analyzed, with predictors of CNS involvement evaluated among patients with EMD. Among 304 patients with EMD, 20 (6.5%) had CNS-MM. CNS involvement occurred a median of 19.2 months after MM diagnosis, though 15% presented at diagnosis. CNS-MM was strongly associated with high-risk cytogenetics (odds ratio [OR], 3.7) and additional visceral EMD (OR, 4.6). Median overall survival (OS) from CNS-MM diagnosis was 4.2 months. Outcomes were significantly improved in patients receiving chimeric antigen receptor T-cell therapy or bispecific antibodies, with a median OS of 19.2 months vs 1.2 months in those who did not receive immune effector therapies. Intrathecal (IT) chemotherapy demonstrated limited and transient benefit. In conclusion, CNS-MM is an aggressive complication enriched in high-risk, multifocal EMD with extremely poor prognosis. Cellular and bispecific therapies show promising activity and may meaningfully improve survival, whereas IT therapy appears to have limited efficacy. Prospective studies are needed to define optimal treatment strategies for CNS-MM.
Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2
Aboelatta, Mohamed A. , Zarka, Jabra , Tchatchua, Nika , Aboelatta, Noureldin A., Johnson, Jeffrey , Jakub, James W. , Desroches, Justin , Wilson-Miller, Justine, Tabiim, Anthony Jagri , Behl, Deepti , Montane, Heather N. , Kottschade, Lisa A. , Dimou, Anastasios , Block, M. , Heath, Elisabeth I. , Doonan, Bently, Seetharam, ­Mahesh , Molina, Julian R. , Charnin, Jonathan E. , Gill, Paula, Lin, Yi, Baral, Binav , Markovic, Svetomir N., Dudek, Arkadiusz Z. , Johnson, Jeffrey E , Tabiim, Anthony , Jakub, James W , Dimou, Anastasios , Montane, Heather N , Dudek, Arkadiusz Z , Zarka, Jabra G , Tchatchua, Nika , Wilson-Miller, Justine L., Doonan, Bently P. , Markovic, Svetomir N.

Mayo Clinic

Current Oncology | June 24, 2026 | Volume: 33 | Issue: 7 | Pages: 379

10.3390/curroncol33070379 | PMID 42505181 Get It

Background/Objectives: Tumor-infiltrating lymphocyte (TIL) therapy is an important option for patients with metastatic melanoma progressing after standard systemic therapy, but real-world data on treatment delivery, toxicity monitoring, and immune recovery remain limited. We evaluated clinical outcomes, treatment tolerance, immune reconstitution, and cardiac biomarker dynamics across three Mayo Clinic sites. Methods: We retrospectively analyzed adults with metastatic melanoma who received lymphodepleting chemotherapy followed by TIL infusion and high-dose interleukin-2 (IL-2) between April 2024 and December 2025. Clinical outcomes, treatment delivery, and adverse events were assessed. Longitudinal immune monitoring included CD4 and CD8 T-cell counts, CD4:CD8 ratio, and immunoglobulin G (IgG) at baseline and follow-up. In a prespecified cardiac sub-cohort, high-sensitivity troponin (hs-Tn) was measured during IL-2 administration to evaluate associations with cardiac events and IL-2 interruption. Results: Thirty-six patients underwent TIL infusion. The objective response rate was 50.0%, including complete responses in 13.9%, and the disease control rate was 72.2%. Median progression-free survival was 3.61 months, and median overall survival was 12.94 months. M1d disease was associated with inferior overall survival on univariable analysis (HR 6.55, 95% CI 2.03–21.17; p = 0.002), with attenuation after multivariable adjustment. Receipt of ≥3 IL-2 doses was associated with longer overall survival on univariable analysis (HR 0.20, 95% CI 0.06–0.64; p = 0.007), but this association also attenuated after adjustment. Longitudinal immune monitoring demonstrated persistent CD4 lymphopenia through 6 months, sustained inversion of the CD4:CD8 ratio, and declining IgG at months 3 and 6. In the cardiac sub-cohort (24 patients; 87 IL-2 doses), post-dose hs-Tn ≥15 ng/L was associated with clinically significant cardiac events (OR 9.6, 95% CI 1.5–60.6; p = 0.016) and IL-2 interruption (OR 3.4, 95% CI 1.1–10.7; p = 0.036). For cardiac events, hs-Tn ≥15 ng/L had 100% sensitivity and 100% negative predictive value. Conclusions: In routine practice, TIL therapy was feasible and active in metastatic melanoma. M1d disease identified a subgroup with poor survival, peri-dose hs-Tn showed promise as a tool to support safer IL-2 delivery, and prolonged CD4 suppression with IgG decline suggests that recovery after TIL therapy extends beyond initial hematologic reconstitution. These findings support prospective validation of biomarker-guided IL-2 monitoring and extended post-treatment immune surveillance.
Arthroscopic Bone Graft Remplissage Using Flexible Bone Allograft for Treatment of Hill‐Sachs Lesions in Anterior Shoulder Instability
Parmar, Romir , Lin, Eugenia A., Tokish, John M. , Tokish, John M , Tummala, Sailesh V , Tummala, Sailesh V. , Lin, Eugenia A.

Mayo Clinic

Arthroscopy Techniques | June 22, 2026 | Volume: 15 | Issue: 7 | Pages: No page available

10.1002/atn2.70012 | PMID 42519643 Get It

Hill‐Sachs lesions are defects in the posterior humeral head from anterior glenoid impaction during dislocation. Left untreated, they can contribute to failure after arthroscopic Bankart repair. Arthroscopic remplissage, involving capsulotenodesis of the posterior capsule and infraspinatus tendon, is the most frequently performed approach to address this lesion. In this technical note, we describe a bone graft remplissage that augments the remplissage with the arthroscopic insertion of a flexible bone graft between the capsule and the sutures to fill the Hill‐Sachs defect. Once secured, the graft is compressed into the defect to create a biological scaffold. This technique combines the simplicity of the knotless remplissage technique with the addition of structural bone graft to Hill‐Sachs lesions.
An Assessment of the Top 100 Most-Liked Orthopaedic Surgery TikTok Videos
Tupper, Connor , Reeson, Emily A., Burdyny, Michael, Cogua, Laura , Lin, Eugenia A., Nellans, Kate W. , Reeson, Emily A.

Mayo Clinic

Journal of Orthopaedic Experience & Innovation | June 20, 2026 | Volume: 7 | Issue: 1 | Pages: No page available

10.60118/001c.156421 Get It

Background The wide reach and unique short audiovisual nature of TikTok make it a potential modality for disseminating information about orthopaedic surgery to both patients and medical professionals. However, only a few recent studies have assessed the purpose and creators of orthopaedic surgery content on TikTok. Methods The top 100 most-liked TikTok videos about orthopaedic surgery topics were included for analysis. Data reflecting video and creator account characteristics were collected. Video validity was determined by three reviewers according to the DISCERN criteria and Kruskal-Wallis H tests were performed to correlate validity to creator and video type. Results The majority of videos were created by orthopaedic surgeons (n=57/100) and for entertainment purposes (n=82/100). Orthopaedic surgeons had the highest DISCERN score (34.7) and greater video reliability compared to all other creator types (H = 59.0-67.1, all p<0.001). Videos made for educational and procedural purposes had the highest DISCERN scores (38.9 and 40.5, respectively) while entertainment videos had lower reliability (H=-56.7 to -113.5, all p<0.05). Conclusion The most popular orthopaedic surgery-related videos on the TikTok platform are primarily being created by orthopaedic surgeons for entertainment purposes. Less frequently were videos made to educate, describe procedures, and explain the lifestyle of an orthopaedic surgeon. Potential applications of utilizing the platform by orthopaedic surgeons include case or research discussions, educational videos on different pathologies, recruitment of prospective students to the field, and entertainment highlighting a day in the life of an orthopaedic surgeon.
Endovascular Thrombectomy for M2 Occlusion
Lin, Michelle , Afia, Mahmoud , Lin, Michelle P

Mayo Clinic

Neurology | June 18, 2026 | Volume: 107 | Issue: 1 | Pages: No page available

10.1212/wnl.0000000000218288 | PMID 42314099 Get It